Title |
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, September 2016
|
DOI | 10.1186/s40425-016-0157-6 |
Pubmed ID | |
Authors |
Marc Uemura, Faisal Faˈak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab |
Abstract |
Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis. This case suggests that Grover's disease is an irAE induced by Ipilimumab. Our immune analysis suggests that Th2 cells may be pathogenic mediators which warrants further study. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 28 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 21% |
Other | 4 | 14% |
Student > Doctoral Student | 2 | 7% |
Student > Ph. D. Student | 2 | 7% |
Student > Bachelor | 1 | 4% |
Other | 5 | 18% |
Unknown | 8 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 46% |
Immunology and Microbiology | 3 | 11% |
Agricultural and Biological Sciences | 1 | 4% |
Unknown | 11 | 39% |